Strategies for Community Adoption of Bispecifics into Treatment of Relapsed/ Refractory Multiple Myeloma
Panelists discuss effective strategies for promoting the adoption of bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM) treatment, emphasizing the importance of educational initiatives, improving care transitions between academic and community settings, addressing misconceptions, and sharing key takeaways and clinical pearls for community oncologists.
Video content above is prompted by the following:
- Which strategies have you found effective in encouraging the adoption of bispecifics in R/R MM treatment?
- Discuss any educational initiatives or protocols that have been successful
- Address common concerns or any hesitations from colleagues.
- How can we improve the transition of care for patients receiving bispecifics between academic centers and community practices?
- Explore any challenges in this transition.
- Share best practices for communication and coordination between settings.
- In your experience, what are the key factors influencing community oncologists' adoption of bispecifics in R/R MM, and how can academic centers support this process?
- Address any misconceptions about bispecifics usage in community settings.
- Identify necessary resources or support systems to increase comfort levels in prescribing and managing bispecifics.
- Explore potential partnerships, training programs, or consultative services between academic and community practices.
- What are some data updates at IMS that you are excited about regarding bispecifics in R/R MM?
- Before we close, I would like each of you to share some key takeaways and clinical pearls on the use of bispecifics for patients with R/R MM for your community colleagues.
- Please share your closing thoughts
Recent Videos
Related Content
